Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc (NQ: MNPR )

0.5894 +0.0092 (+1.59%)
Streaming Delayed Price Updated: 12:58 PM EDT, Aug 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Monopar Therapeutics Inc

< Previous 1 2 Next >
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
Interim Analysis Planned for Q1 2023 
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.